BMS-707035, also known as BMS707035 (CAS: 729607-74-3), is a small molecule drug candidate that is being developed for the treatment of cancer. This product works by inhibiting a protein called PAK1, which plays a role in the growth and spread of cancer cells.
Chemical name: N-(4-fluoro-2-methylphenyl)-2-(4-(morpholinomethyl)phenyl)acetamide
Molecular formula: C19H24FN3O2
Formula weight: 341.41 g/mol
CAS No: 729607-74-3
Top ten keywords from Google and Synonyms:
Synonyms: BMS-707035, BMS 707035, N-(4-fluoro-2-methylphenyl)-2-(4-(morpholinomethyl)phenyl)acetamide
Health benefits of BMS-707035:
The primary health benefit of BMS-707035 is its potential to inhibit the growth and spread of cancer cells. By inhibiting PAK1, this medication may help prevent tumor growth and improve outcomes for patients with cancer.
Potential effects of BMS-707035:
BMS-707035 works by inhibiting PAK1, a protein that plays a role in the growth and spread of cancer cells. In preclinical studies, this medication has demonstrated significant anticancer activity, including induction of apoptosis (programmed cell death) and inhibition of tumor growth. Additionally, BMS-707035 has been shown to enhance the effectiveness of other chemotherapy drugs in treating cancer.
Product mechanism:
BMS-707035 works by inhibiting PAK1, a protein that plays a key role in the growth and spread of cancer cells. By inhibiting PAK1, this medication can help prevent tumor growth and improve outcomes for patients with cancer. Additionally, BMS-707035 has been shown to enhance the effectiveness of other chemotherapy drugs in treating cancer.
Safety:
BMS-707035 is currently in clinical trials and its safety profile is still being evaluated. However, like any medication, it does carry some risks and potential side effects. Before taking this medication, patients should discuss their medical history and any current medications with their healthcare provider to ensure that it is safe for them to take.
Side effects of BMS-707035:
Common side effects of BMS-707035 are not yet fully known, as this medication is still being evaluated in clinical trials. However, potential side effects may include gastrointestinal symptoms, fatigue, and dermatological reactions. Patients who experience any of these symptoms while taking this medication should contact their healthcare provider immediately.
Dosing information:
The recommended dose of BMS-707035 varies depending on the patient's medical history and condition. It is important for patients to follow their healthcare provider's instructions regarding dosing and administration of this medication.
Conclusion:
BMS-707035 is a small molecule drug candidate that is being developed for the treatment of cancer. By inhibiting PAK1, this medication may help prevent tumor growth and improve outcomes for patients with cancer. While still being evaluated in clinical trials, BMS-707035 has demonstrated significant anticancer activity in preclinical studies and may have the potential to enhance the effectiveness of other chemotherapy drugs. As with any medication, it is important for patients to discuss their medical history and any current medications with their healthcare provider before taking it. Overall, BMS-707035 is a promising drug candidate that may hold significant potential for the treatment of cancer.
